Fresenius Medical Care AG (NYSE:FMS)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $44.31, but opened at $44.84. Fresenius Medical Care AG shares last traded at $45.55, with a volume of 186,376 shares traded.

FMS has been the subject of a number of research reports. DZ Bank AG restated a “sell” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 10th. Robert W. Baird restated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Monday, May 16th. Sanford C. Bernstein initiated coverage on shares of Fresenius Medical Care AG in a research report on Monday, April 11th. They set an “outperform” rating for the company. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research report on Friday, July 8th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, May 24th. Two analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $42.50.

The stock has a market cap of $27.86 billion and a price-to-earnings ratio of 26.54. The firm’s 50 day moving average is $43.03 and its 200 day moving average is $42.92.

Fresenius Medical Care AG (NYSE:FMS) last posted its earnings results on Tuesday, May 3rd. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.33. The firm had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same period last year, the firm earned $0.69 earnings per share. Fresenius Medical Care AG’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect that Fresenius Medical Care AG will post $2.03 EPS for the current year.

Other large investors recently added to or reduced their stakes in the company. Comerica Bank boosted its stake in Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock worth $1,486,000 after buying an additional 1,798 shares in the last quarter. WBI Investments Inc. bought a new stake in Fresenius Medical Care AG during the fourth quarter worth about $2,249,000. Bank of Montreal Can boosted its stake in Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock worth $4,493,000 after buying an additional 3,694 shares in the last quarter. Finally, US Bancorp DE boosted its stake in Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock worth $11,503,000 after buying an additional 10,479 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.